Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
14.01.2019 23:15:00

Arfinn Med Launches First-Ever Physician Portal for Medical Cannabis Treatments and Efficacies

DALLAS, Jan. 14, 2019 /PRNewswire/ -- Arfinn Med, a full-service medical education company, announced today the launch of its clinician-based medical cannabis efficacy portal. Designed for licensed medical professionals, the portal allows physicians to properly track, report and share HIPAA-compliant benchmark data for prescribing medical cannabis to patients. As a free tool for physicians, Arfinn Med offers a new way to enhance treatment plans and practices in an emerging industry.  

Headquartered in Tampa, FL, Arfinn Med was created to address the demand for real-time data surrounding treatment plans and to act as a liaison between the growing medical marijuana industry and medical professionals, as well as stakeholders. The free portal includes four components – Reports, Community, Industry News and Resources. Within the portal, medical professionals can obtain peer-based reports on treatment effectiveness, daily dosage, delivery method and other information specific to patient demographics. Arfinn Med also provides medical professionals with access to industry news, trends, specialized groups, forums, blogs and other medical research. Any licensed medical professional is able to register for the portal for free, regardless of state location and medical marijuana legalization.

"We are pleased to launch Arfinn Med as the first collaborative and insight-driven medical marijuana portal for medical professionals," said James West, founder and CEO of Arfinn Med. "Our goal is to provide physicians with access to benchmark data, industry news and relevant, peer-to-peer discussions as a tool to further enhance their practices."

In addition to the reporting and tracking components, the portal offers a patient engagement tool to allow physicians to communicate in real-time with patients about their treatments plans and outcomes, increasing efficacy rates and the probability that patients return to their prescribing physician's practice. 

After rolling out the platform to select physicians in October 2018, Dr. Mark Hashim, a board-certified physician and member of the Society of Cannabis Clinicians, began using the platform to enhance his medical marijuana practice, The Herbal Clinic MD.

"As a cannabis physician, it is such a relief to have a portal to share with other physicians about conditions and outcomes," said Dr. Hashim. "It is such an emerging field and the more we can learn what works well, the better we are able to achieve a positive result for patients and improve their quality of life. This is a revolutionary idea that will not only benefit the cannabis patients, but will help guide physicians on decisions about treating various ailments."

For more information or to register for Arfinn Med, visit www.ArfinnMed.com. 

About Arfinn Med

Arfinn Med is the first clinician-based medical professional and patient efficacy portal for medical cannabis treatments. Launched in January 2019, the free collaborative portal allows medical professionals to register, share, research and communicate about the best efficacy practices for medical cannabis. Arfinn Med is designed to connect medical professionals via the portal to educate and provide physicians with benchmark data and industry trends to lead to effective treatments for patients. For more information and to register for free, visit www.arfinnmed.com.

Media Contact:
Bolt Public Relations
(469) 340-7368
arfinn@boltpr.com

Cision View original content:http://www.prnewswire.com/news-releases/arfinn-med-launches-first-ever-physician-portal-for-medical-cannabis-treatments-and-efficacies-300777904.html

SOURCE Arfinn Med

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!